SCHEMBL172068

SCHEMBL172068

CC(C)(C)OC(=O)N1CCn2nc(N)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.41
ESR2 Q92731 1/20 0.36
KDM1A O60341 1/20 0.36
SMARCA2 P51531 2/20 0.35
SMARCA4 P51532 2/20 0.35
PBRM1 Q86U86 2/20 0.35
MPO P05164 1/20 0.35
SCN5A Q14524 1/20 0.34
SCN9A Q15858 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
MAP4K4 O95819 1/20 0.33
USP2 O75604 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GRM5 P41594 1/20 0.33
GPR119 Q8TDV5 1/20 0.33
HSP90AA1 P07900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22102671 0.92 GRM5 (0.41) NR1H2ESR2MPOGRM5
SCHEMBL798568 0.84 TP53 (0.41) NR1H2ESR2KDM1AKDM4EMAPT
SCHEMBL22074956 0.83 ESR2 (0.36) NR1H2ESR2KDM1AKDM4EMAPT
SCHEMBL170000 0.82 ESR2 (0.36) NR1H2ESR2KDM1ASCN5ASCN9A
SCHEMBL25594892 0.82 ESR2 (0.36) NR1H2ESR2KDM1ASCN5ASCN9A
SCHEMBL18593216 0.81 CHRM2 (0.38) NR1H2ESR2KDM1ASMARCA2SMARCA4
SCHEMBL169996 0.80 ALDH1A1 (0.42) NR1H2ESR2KDM4EMAPTTHRB
SCHEMBL12307554 0.79 PIK3CG (0.36) NR1H2ESR2MAPTHDAC1HDAC6
SCHEMBL12307395 0.77 GCK (0.35) NR1H2ESR2HDAC1HDAC6SMN1; SMN2
SCHEMBL22279667 0.76 MAP4K4 (0.39) NR1H2KDM1ASMARCA2SMARCA4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2426135-A1 UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY Shionogi&Co., Ltd. (JP) 2012-03-07 EP disclosed
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-22 US disclosed
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY SHIONOGI & CO., LTD. (JP) 2011-09-22 US disclosed
EP-2327704-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY Shionogi&Co., Ltd. (JP) 2011-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110230472-A1 RING-FUSED AZOLE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY PIK3R5, PIK3R4, PIK3R1 NR1H2 489/4885ESR2 2102/4885KDM1A 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.